Current Clinical Trials of the Anti-VEGF Monoclonal Antibody Bevacizumab
August 1st 2001Given the well-established role of angiogenesis (or new blood vessel formation) in tumor growth and metastasis, antiangiogenic therapy, a concept first proposed by Dr. Judah Folkman,[1] has become increasingly recognized as a promising